Detection of immunogenic cell death and its relevance for cancer therapy

Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell death & disease Ročník 11; číslo 11; s. 1013 - 13
Hlavní autoři: Fucikova, Jitka, Kepp, Oliver, Kasikova, Lenka, Petroni, Giulia, Yamazaki, Takahiro, Liu, Peng, Zhao, Liwei, Spisek, Radek, Kroemer, Guido, Galluzzi, Lorenzo
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 26.11.2020
Springer Nature B.V
Nature Publishing Group
Témata:
ISSN:2041-4889, 2041-4889
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Chemotherapy, radiation therapy, as well as targeted anticancer agents can induce clinically relevant tumor-targeting immune responses, which critically rely on the antigenicity of malignant cells and their capacity to generate adjuvant signals. In particular, immunogenic cell death (ICD) is accompanied by the exposure and release of numerous damage-associated molecular patterns (DAMPs), which altogether confer a robust adjuvanticity to dying cancer cells, as they favor the recruitment and activation of antigen-presenting cells. ICD-associated DAMPs include surface-exposed calreticulin (CALR) as well as secreted ATP, annexin A1 (ANXA1), type I interferon, and high-mobility group box 1 (HMGB1). Additional hallmarks of ICD encompass the phosphorylation of eukaryotic translation initiation factor 2 subunit-α (EIF2S1, better known as eIF2α), the activation of autophagy, and a global arrest in transcription and translation. Here, we outline methodological approaches for measuring ICD markers in vitro and ex vivo for the discovery of next-generation antineoplastic agents, the development of personalized anticancer regimens, and the identification of optimal therapeutic combinations for the clinical management of cancer.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
PMCID: PMC7691519
ISSN:2041-4889
2041-4889
DOI:10.1038/s41419-020-03221-2